Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to test the impact of a multilevel decision support intervention on informed decisions about breast MRI among high-risk Black and Latina women. Participants (N=80) will be randomized to (1) enhanced usual care (risk assessment + referral to nurse practitioner) or (2) decision support (enhanced usual care + decision aid). Assessments will take place at baseline (T0) and 1-month post-intervention (T1). The primary outcome is informed decisions about breast MRI at T1.
The aim of this study is to evaluate whether the decision support intervention produces a clinically significant change in informed decisions about breast MRI. An informed decision is defined as a decision that is made with sufficient knowledge, and is in line with the person's preferences. The investigators will achieve this aim through a randomized controlled trial. This trial adheres to well-established design and reporting criteria for behavioral intervention studies to ensure patient safety and examine trial outcomes.<br> <br> Research Design. The main hypothesis is that participants receiving the decision support intervention will be more likely to make an informed decision about breast MRI v. participants receiving enhanced usual care. To test this hypothesis, participants (N=80) will be randomized to one of two arms: (1) enhanced usual care (breast cancer risk assessment + referral to nurse practitioner) or (2) decision support (enhanced usual care + decision aid). This design will allow us to examine the effect of decision support above and beyond breast cancer risk assessment and notification.<br> <br> Participants and Eligibility. The investigators will enroll a total of 80 Black and Latina women with high risk for breast cancer, defined as ≥20% lifetime risk for breast cancer. Participants will be recruited from the Ralph Lauren Center (RLC), a community-based clinic in Washington, DC, affiliated with the Georgetown Lombardi Comprehensive Cancer Center. <br> <br> Access. Participants must adequately speak English or Spanish to participate; the investigators will include those who are bilingual. To support access for women who report Spanish as their primary language, a bilingual/bicultural research assistant will approach, recruit, and complete assessments with these participants and provide additional study support as needed. In addition, all study materials will be available in both English and Spanish.<br> <br> Recruitment and Enrollment. During intake interviews for new RLC patients, navigators will administer the NCI Breast Cancer Risk Assessment Tool (BCRAT) via phone, enter responses into the BCRAT website in real-time, calculate lifetime breast cancer risk, and document BCRAT results in RLC's HIPAA-compliant, web-based patient tracking platform (RIPPLE©). The investigators estimate that this process will take <5 minutes to complete. The BCRAT provides estimated lifetime risk for breast cancer to inform use of breast MRI, and will be used to determine study eligibility. At this point, all women will continue routine mammography navigation. Women will receive mammogram results via mail; study staff will confirm normal mammogram results via the EMR. A research assistant (RA) will then contact high-risk women with a negative mammogram via phone, confirm eligibility, introduce the study, answer any questions, obtain verbal informed consent, and conduct the baseline assessment. Participants will be randomized immediately following the baseline assessment.<br> <br> Intervention Conditions. Participants in the Enhanced Usual Care arm will be mailed a letter with their estimated lifetime risk for breast cancer per the NCI Breast Cancer Risk Assessment Tool (BCRAT), information about screening breast MRI, and instructions for contacting the nurse practitioner (NP) at RLC with questions. Participants in the Decision Support arm will receive the same letter as those in the Enhanced Usual Care arm. In addition, they will be sent a decision aid via mail or email (as preferred). The decision aid describes two different breast cancer screening plans: (1) annual mammography only; and (2) annual mammography plus annual breast MRI. The decision aid provides balanced information about breast MRI, including its risks, limitations, and benefits. The decision aid will emphasize that there is no 'correct' decision and women should pick the plan that is right for them. It will also include: (1) facts about breast cancer and breast cancer risk (e.g., what does it mean to be at high risk, factors contributing to breast cancer risk, etc.); (2) answers to frequently asked questions about breast cancer screening; (3) an interactive exercise to clarify screening preferences; (4) information about cost/insurance coverage for breast cancer screening; and (5) instructions for accessing breast cancer screening (both mammogram and MRI) via RLC. The decision aid will emphasize that the nurse practitioner (NP) at RLC can provide a referral for mammogram and/or MRI to interested patients.<br> <br> Randomization. A computer-generated randomization table will be used to assign participants (N=80) to intervention conditions (n=40 per condition). Randomization will be stratified by race/ethnicity in random block sizes of 4, 8, or 12 to ensure balance across conditions.<br> <br> Measures. System-level data (i.e., CBCC patients navigated, high-risk women identified) will be obtained via EMR review. Patient-level data will be obtained via EMR review and participant self-report. Participants will complete self-report measures at baseline (T0) and 1-month post-intervention (T1) in-person or via phone with the assistance of a bilingual/bicultural RA (as preferred). The timing of the T1 assessment was selected in order to provide enough time for the intervention participants to receive/use the decision aid. Thus, the T1 survey allows for examination of the short-term effects of the decision aid. All measures will be available in English and Spanish. As noted above, a certified translator will be used to create a Spanish-language version.<br> <br> Hypotheses. The investigators will test the following two hypotheses:<br>
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Enhanced Usual Care | Active Comparator | Participants in this arm will be mailed a letter with their estimated lifetime risk for breast cancer per the NCI Breast Cancer Risk Assessment Tool (BCRAT), information about screening breast MRI, and instructions for contacting the nurse practitioner (NP) at the Ralph Lauren Center (RLC) with questions. |
|
| Decision Support | Experimental | Participants in this arm will receive the same letter as those in the Enhanced Usual Care arm. In addition, they will be sent the decision aid via mail or email (as preferred). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Enhanced Usual Care | Behavioral | Risk assessment and notification, referral to nurse practitioner (NP) at the Ralph Lauren Center (RLC) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Informed decisions about breast MRI | According to the Multidimensional Measure of Informed Choice, an informed decision is made with adequate knowledge and consistent with the respondent's preferences. Thus, two groups are classified as having made an informed decision: (1) those with adequate MRI knowledge, whose preferences align with screening with mammogram + MRI, and who intend to undergo MRI; and (2) those with adequate MRI knowledge, whose preferences align with screening with mammogram only, and who do not intend to undergo MRI. The knowledge, preferences, and intentions scores collected at T1 will be used to identify informed decisions. | 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| Decision Satisfaction | The Satisfaction With Decision (SWD) scale includes 6 items rated from "strongly disagree" (1) to "strongly agree" (5). Items are averaged to create a total score ranging from 1-5 (higher=greater satisfaction). Instructions will specify decisions about breast cancer screening. | 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| MRI Knowledge | This breast MRI knowledge scale includes 10 true/false items based on the content of the breast MRI decision aid. Items are scored as correct (1) or incorrect (0); item scores are summed to create total scores (higher=greater knowledge). Adequate knowledge is specified as ≥50% correct. | 1 month |
| Screening Preferences |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Claire C. Conley, PhD | Contact | 2026875086 | claire.conley@georgetown.edu |
| Name | Affiliation | Role |
|---|---|---|
| Claire C. Conley, PhD | Georgetown University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Georgetown University | Recruiting | Washington D.C. | District of Columbia | 20007 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Decision Support | Behavioral | The decision aid describes two different breast cancer screening plans: (1) annual mammography only; and (2) annual mammography plus annual breast MRI. The decision aid provides balanced information about breast MRI, including its risks, limitations, and benefits. |
|
| Decisional Conflict |
The low-literacy version of the Decisional Conflict Scale (DCS) includes 10 items rated as "yes" (0), "unsure" (2), or "no" (4). Items are summed and transformed to create total scores ranging from 0-100 (higher=more conflict). Instructions will specify decisions about breast cancer screening. |
| 1 month |
Respondents will rate factors that are viewed as important by people deciding about breast cancer screening (e.g., length of procedure, false positives, cost, etc.) on a 12-point scale ranging from "not at all important" (0) to "extremely important" (11). Items are averaged to create are averaged to create a total score ranging from 0-11 (lower=preference for screening with mammogram only, higher=preference for screening with mammogram + breast MRI). |
| 1 month |
| Screening Intentions | Participants will indicate screening intentions on a single item with a 7-point scale ranging from "mammogram only" (-3) to "mammogram + breast MRI" (3), with "unsure" as the mid-point (0). | 1 month |
| Enacted Decision | Receipt of MRI (yes/no) will be assessed via EMR review. | 6 months |
| Dosage/Fidelity | Self-reported receipt and use of the decision aid. | 1 month |
| Preparation for Decision Making | The 10-item Preparation for Decision Making (PDM) Scale assesses opinions about the effect of the decision aid. Items are rated from "not at all" (1) to "a great deal" (5). Items are summed and transformed to create total scores ranging from 0-100 (higher=more prepared for decision making). | 1 month |
| Decision Aid Bias | Participants will indicate whether the decision aid suggested that they should screen with mammogram (-1), screen with mammogram + breast MRI (1), or neither (0). | 1 month |
| ID | Term |
|---|---|
| D061325 | Hereditary Breast and Ovarian Cancer Syndrome |
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D010051 | Ovarian Neoplasms |
| D004701 | Endocrine Gland Neoplasms |
| D009386 | Neoplastic Syndromes, Hereditary |
| D010049 | Ovarian Diseases |
| D000291 | Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D000091662 | Genital Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |
Not provided
Not provided